Show simple item record

dc.contributor.authorChallberg, Jen_US
dc.contributor.authorAshcroft, Len_US
dc.contributor.authorLalloo, Fen_US
dc.contributor.authorEckersley, Ben_US
dc.contributor.authorClayton, Ren_US
dc.contributor.authorHopwood, Pen_US
dc.contributor.authorSelby, Pen_US
dc.contributor.authorHowell, Aen_US
dc.contributor.authorEvans, DGen_US
dc.date.accessioned2018-08-13T14:09:06Z
dc.date.issued2011-06-28en_US
dc.identifier1en_US
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2011, 105 pp. 22 - 27en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2326
dc.identifier.eissn1532-1827en_US
dc.identifier.doi10.1038/bjc.2011.202en_US
dc.description.abstractBACKGROUND: Women at high ovarian cancer risk, especially those with mutations in BRCA1/BRCA2, are encouraged to undergo bilateral risk-reducing salpingo-oophorectomy (BRRSPO) prior to the natural menopause. The decision to use HRT to cover the period of oestrogen deprivation up to 50 years of age is difficult because of balancing the considerations of breast cancer risk, bone and cardiovascular health. METHODS: We reviewed by questionnaire 289 women after BRRSPO aged <= 48 years because of high ovarian cancer risk; 212 (73%) of women responded. RESULTS: Previous HRT users (n = 67) had significantly worse endocrine symptom scores than 67 current users (P = 0.006). A total of 123 (58%) of women had >= 24 months of oestrogen deprivation <50 years with 78 (37%) never taking HRT. Bone density (DXA) evaluations were available on 119 (56%) women: bone loss with a T score of <=-1.0 was present in 5 out of 31 (16%) women with no period of oestrogen deprivation <50 years compared with 37 out of 78 (47%) of those with >= 24 months of oestrogen deprivation (P = 0.03). INTERPRETATION: Women undergoing BRRSPO <50 years should be counselled concerning the risks/benefits of HRT, taking into consideration the benefits on symptoms, bone health and cardiovascular health, and that the risks of breast cancer from oestrogen-only HRT appear to be relatively small. British Journal of Cancer (2011) 105, 22-27. doi:10.1038/bjc.2011.202 www.bjcancer.com Published online 7 June 2011 (C) 2011 Cancer Research UKen_US
dc.format.extent22 - 27en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherNATURE PUBLISHING GROUPen_US
dc.titleMenopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRTen_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/bjc.2011.202en_US
rioxxterms.licenseref.startdate2011-06-28en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBRITISH JOURNAL OF CANCERen_US
pubs.notesaffiliation: Evans, DG (Reprint Author), Univ Manchester, Dept Med Genet, Manchester Acad Hlth Sci Ctr, Cent Manchester Fdn Trust,St Marys Hosp, 6th Floor,Oxford Rd, Manchester M13 9WL, Lancs, England. Challberg, J.; Lalloo, F.; Evans, D. G., Univ Manchester, Dept Med Genet, Manchester Acad Hlth Sci Ctr, Cent Manchester Fdn Trust,St Marys Hosp, Manchester M13 9WL, Lancs, England. Ashcroft, L.; Howell, A., Univ Manchester, Manchester Breast Ctr, Christie NHS Fdn Trust, Manchester M20 4BX, Lancs, England. Eckersley, B.; Howell, A.; Evans, D. G., Univ Hosp S Manchester NHS Trust, Genesis Breast Canc Prevent Ctr, Breast Screening Serv, Manchester M23 9LT, Lancs, England. Clayton, R.; Selby, P., Univ Manchester, Dept Med, Manchester Acad Hlth Sci Ctr, Cent Manchester Fdn Trust, Manchester M13 9WL, Lancs, England. Hopwood, P., Inst Canc Res, Dept Psychonchol, Surrey, England. keywords: oophorectomy; HRT; osteoporosis; osteopenia; menopause; breast cancer keywords-plus: HORMONE REPLACEMENT THERAPY; HEREDITARY OVARIAN-CANCER; QUALITY-OF-LIFE; BREAST-CANCER; PROPHYLACTIC OOPHORECTOMY; BRCA2 MUTATIONS; POSTMENOPAUSAL WOMEN; PREMATURE MENOPAUSE; CARRIERS; PENETRANCE research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] orcid-numbers: Howell, Anthony/0000-0002-6233-719X Selby, Peter/0000-0001-9465-9268 Evans, Gareth/0000-0002-8482-5784 funding-acknowledgement: Manchester Biomedical Research Centre, NIHR; Genesis Breast Cancer Prevention Appeal funding-text: We acknowledge the support of the Manchester Biomedical Research Centre, NIHR and the Genesis Breast Cancer Prevention Appeal. We also thank Pam Coates for undertaking the DXA scans. number-of-cited-references: 35 times-cited: 35 usage-count-last-180-days: 0 usage-count-since-2013: 5 journal-iso: Br. J. Cancer doc-delivery-number: 784TZ unique-id: ISI:000292182400005 oa: gold_or_bronze da: 2018-08-13en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Psychology Research Group
pubs.volume105en_US
pubs.embargo.termsNot knownen_US
icr.researchteamPsychology Research Groupen_US
dc.contributor.icrauthorHopwood, Pen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record